Insights from 2023 SABCS


 

SABCS 2023 Insights: "CompassHER2 RD Trial - Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients With Residual HER2+ Invasive BC"

304 views
December 15, 2023
Comments 0
Login to view comments. Click here to Login